Prospective SPECT-CT organ dosimetry-driven radiation-absorbed dose escalation using the In-111 (111In)/yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin ®) theranostic pair in patients with lymphoma at myeloablative dose levels

Authors

Richard L Wahl, Washington University School of Medicine in St. Louis
Eric C Frey, Johns Hopkins University
Heather A Jacene, Johns Hopkins University
Brad S Kahl, Washington University School of Medicine in St. Louis
Steven Piantadosi, Johns Hopkins University
Jesus A Bianco, Johns Hopkins University
Richard J Hammes, University of Wisconsin-Madison
Miah Jung, Johns Hopkins University
Wayne Kasecamp, Johns Hopkins University
Bin He, Johns Hopkins University
George Sgouros, Johns Hopkins University
Ian W Flinn, Johns Hopkins University
Lode J Swinnen, Johns Hopkins University

Journal

Cancers (Basel)

Publication Date

2021

Volume

13

Issue

11

First Page

2828

Document Type

Open Access Publication

DOI

10.3390/cancers13112828

Rights and Permissions

Wahl RL, Frey EC, Jacene HA, et al. Prospective SPECT-CT Organ Dosimetry-Driven Radiation-Absorbed Dose Escalation Using the In-111 (111In)/Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) Theranostic Pair in Patients with Lymphoma at Myeloablative Dose Levels. Cancers (Basel). 2021;13(11):2828. Published 2021 Jun 6. doi:10.3390/cancers13112828

Recommended Citation

Wahl, Richard L; Frey, Eric C; Jacene, Heather A; Kahl, Brad S; Piantadosi, Steven; Bianco, Jesus A; Hammes, Richard J; Jung, Miah; Kasecamp, Wayne; He, Bin; Sgouros, George; Flinn, Ian W; and Swinnen, Lode J, "Prospective SPECT-CT organ dosimetry-driven radiation-absorbed dose escalation using the In-111 (111In)/yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin ®) theranostic pair in patients with lymphoma at myeloablative dose levels." Cancers (Basel). 13, 11. 2828 (2021).
https://digitalcommons.wustl.edu/open_access_pubs/10446